ZLY28

N/A

Report date: 2023/04/24 17:55:29
NMEFirst In Class

Base Information

Drug NameZLY28
Drug Alias NameZLY28ZLY-28
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBile acid receptor FXR modulatorsFatty Acid Binding Protein 1 inhibitors
TargetsBile acid receptor FXRFatty Acid Binding Protein 1
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGuangdong Pharmaceutical University
China Registration ClassN/A

Develop Information

Active CompaniesGuangdong Pharmaceutical University
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A